Disorders and Treatment
- Mental Illness
- Bipolar Disorder
- Mood Disorders
- Borderline Personality
- Mental Health Diagnosis
- Mental Health Treatments
- Alternative Meds
- Case Studies
If you or somebody you know has Parkinson's disease (PD), you have surely experienced the sense of helplessness this condition can trigger. PD patients face a wide array of challenges both physical and psychological; although less obvious to the eye, the latter can be just as daunting to overcome, and just as potentially damaging, as the former.
Take one of the worst sources of stress for PD patients: Freezing or "off" episodes—periods of immobility that last from one to several hours. First-line PD therapy involves drugs that keep these episodes at bay, but after a few years these treatments work less well. Subsequent treatments help, but their effects can be limited and slow to kick in. When they are too slow, the patient enters an "off" episode.
If you have experienced an "off" episode firsthand—or have observed a family member or loved one experience one—you know how traumatic they can be. They are potent sources of psychological trauma for three reasons:
Working in tandem, the lack of advance warning, painful treatment, and continual dependence on a caregiver is almost guaranteed to trigger psychological trauma in the PD patient who experiences "off" episodes. Thus the demand for better treatments is rooted in two needs: First, PD patients need more effective and less cumbersome treatment options. Second, just as importantly, they need to feel they are in control of their lives. The psychological costs will continue to be excessive until this happens.
Cynapsus Therapeutics, a small Toronto company, is trying a novel approach to overcome the limitations of the injectable form of apomorphine. Cynapsus has developed APL-130277, a dual-layer, sublingual thin-film strip, similar to Listerine® Breath Strips. Placed under the tongue, the strip dissolves in about 1.5 minutes, delivering apomorphine to the bloodstream in a similar time frame and concentration as the injectable dose.
If APL-130277 is cleared for use by the FDA, it holds the potential to open a new chapter in PD treatment, ensuring "off" episodes are rescued quickly, providing the patient the ability to move freely, thanks to a much more convenient and tolerable delivery method.
And that physical freedom could potentially be accompanied by an escape from the psychological trauma that has dogged some PD patients for too long.
Anthony Giovinazzo is President and CEO of Cynapsus Therapeutics, Inc., which is developing the only non-injectable (sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease.
The information provided on the PsyWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of PsyWeb.com nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.